Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

The Danish drugmaker has launched a new online pharmacy called NovoCare Pharmacy to cut out the middlemen it so frequently ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Both Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,300 per month ... Eli Lilly reduced the monthly price of lower-dosage vials of Zepbound by $50 for cash-paying consumers ...

Now, the company is adding the 7.5 mg and 10 mg vials. And on Wednesday the maker of Wegovy, a similar weight-loss drug, announced that it, too, would offer direct-to-consumer discounts for ...